• Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.
Auteur:Colombo, Nicoletta; Speyer, J L; Green, M; Canetta, R; Beller, U; Wernz, J C; Meyers, Michel; Widman, T; Blum, R H; Piccart-Gebhart, Martine
Informations sur la publication:Cancer chemotherapy and pharmacology, 23, 5, page (323-328)
Statut de publication:Publié, 1989
Sujet CREF:Sciences bio-médicales et agricoles
MeSH keywords:Acute Disease
Antineoplastic Agents -- administration & dosage
Antineoplastic Agents -- adverse effects
Blood -- drug effects
Carcinoma -- blood
Carcinoma -- complications
Carcinoma -- drug therapy
Creatinine -- blood
Drug Evaluation
Kidney Failure, Chronic -- blood
Neoplasm Recurrence, Local -- blood
Neoplasm Recurrence, Local -- complications
Neoplasm Recurrence, Local -- drug therapy
Organoplatinum Compounds -- administration & dosage
Organoplatinum Compounds -- adverse effects
Ovarian Neoplasms -- blood
Ovarian Neoplasms -- complications
Ovarian Neoplasms -- drug therapy
Platelet Count -- drug effects
Prospective Studies
Thrombocytopenia -- blood
Thrombocytopenia -- chemically induced
Time Factors
Note générale:Journal Article
Research Support, Non-U.S. Gov't